Health Ministry deliberating report on ‘faulty’ hip replacement surgeries by MNC: Nadda

New Delhi:Union Health Minister JP Nadda today said his ministry is holding deliberations on an expert panel’s report on alleged faulty hip replacements surgeries by a multinational company in India and will take necessary steps.

“We are deliberating on it,” he told reporters here, without elaborating.

His comments came after reports appeared in the media, claiming pharma giant Johnson and Johnson “suppressed” facts on the harm caused by surgeries which were conducted on patients in India using “faulty” hip replacement systems.

According to reports, the expert committee, set up to investigate complaints about hip implant devices, has suggested that the company pay compensation of around Rs 20 lakh to the affected patients.

Prodded further about the committee’s report on the faulty hip replacement surgeries and why the company was still being allowed to continue with these surgeries, Nadda said, “I share your concerns. We will take necessary steps accordingly.”

The Health Ministry on August 25 said that following the reports which appeared in the media, it has directed the formation of state level committees for hearing the grievances.

“The compensation to the patients will be decided based on examinations done on them. Now we have to assess how many (patients) are affected due to it. That is why state committees will be formed.

“Apart from this, advertisements will also be put up in prominent newspapers so that the affected patients know about this and can approach the committee with their grievances,” the Drugs Controller General of India Eswara Reddy had told .

Sources in the Ministry said that once the state committees examine those affected, they will give their recommendations to the expert committee at the centre and accordingly the company will be asked to compensate.

Reports quoting the expert committee findings say that over 3,600 patients with faulty implants remain untraceable, and that at least four deaths have been reported among these patients.

  • Related Posts

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Ludhiana police seize 56 kg ganja; courier warehouse under scanner

    The recovery has raised serious concerns over alleged lapses in parcel screening and monitoring within the logistics chain. The special cell of Ludhiana police has seized more than two quintals…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise